|
Liver Cirrhosis, Experimental
|
0.300 |
Biomarker
|
disease |
CTD_human |
Systems level analysis and identification of pathways and networks associated with liver fibrosis.
|
25380136 |
2014 |
|
Malignant neoplasm of breast
|
0.300 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Catalepsy
|
0.010 |
Biomarker
|
disease |
BEFREE |
KNT-127 produced neither catalepsy nor convulsive effects.
|
31654658 |
2020 |
|
Mental Depression
|
0.010 |
Biomarker
|
disease |
BEFREE |
We have also demonstrated that KNT-127 showed potent and rapid antidepressant-like effects in rat models of depression.
|
31654658 |
2020 |
|
Depressive disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
We have also demonstrated that KNT-127 showed potent and rapid antidepressant-like effects in rat models of depression.
|
31654658 |
2020 |
|
Depressed mood
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
We have also demonstrated that KNT-127 showed potent and rapid antidepressant-like effects in rat models of depression.
|
31654658 |
2020 |
|
Anxiety Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
These observations led us to hypothesize that KNT-127 might be an appropriate therapeutic agent for anxiety disorders when combined with exposure therapy.
|
30686587 |
2019 |
|
Kidney Failure, Chronic
|
0.010 |
Biomarker
|
disease |
BEFREE |
The risk of progression to ESRD of patients with CG II and III was significantly higher than that of patients with CG I.
|
30367317 |
2019 |
|
Squamous cell carcinoma of skin
|
0.010 |
Biomarker
|
disease |
BEFREE |
MALAT1-KTN1-EGFR regulatory axis promotes the development of cutaneous squamous cell carcinoma.
|
30683916 |
2019 |
|
Chronic kidney disease stage 5
|
0.010 |
Biomarker
|
disease |
BEFREE |
The risk of progression to ESRD of patients with CG II and III was significantly higher than that of patients with CG I.
|
30367317 |
2019 |
|
Seizures
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
For behavioral experiments, male C57BL6/J mice were injected intraperitoneally with either KNT-127 (30 mg/kg) or SNC80 (30 mg/kg) and monitored for convulsions and subsequent catalepsy-like behavior for 10 min immediately after drug treatment.
|
29477045 |
2018 |
|
Convulsions
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
For behavioral experiments, male C57BL6/J mice were injected intraperitoneally with either KNT-127 (30 mg/kg) or SNC80 (30 mg/kg) and monitored for convulsions and subsequent catalepsy-like behavior for 10 min immediately after drug treatment.
|
29477045 |
2018 |
|
Schizophrenia
|
0.010 |
Biomarker
|
disease |
BEFREE |
To identify markers of disks, large homolog 2 (DLG2), FAT atypical cadherin 3 (FAT3), kinectin1 (KTN1), deleted in colorectal carcinoma (DCC), and glycogen synthase kinase-3β (GSK3β) that contribute to the genetic susceptibility to schizophrenia, we systematically screened for polymorphisms in the functional regions of these genes.
|
27055860 |
2016 |
|
Uveal melanoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Other genes, i.e., TP53BP1, CSMD1, TTC28, DLK2, and KTN1, were also found to harbor somatic mutations in more than one individual, possibly indicating a previously undescribed association with UM pathogenesis.
|
27745836 |
2016 |
|
Neoplasms
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Tumor 1 had an unbalanced t(2;14)(p23;q22) translocation which led to the fusion gene KTN1-ALK.
|
25795305 |
2015 |
|
Diabetes
|
0.010 |
Biomarker
|
disease |
BEFREE |
By multivariate analysis, diabetes (95% confidence interval [CI]: 1.9-13.2, P< .001), prior ESBL E coli colonization (<90 days) (95% CI: 1.2-67.8, P< .001), recent receipt of antibiotics (<90 days) (95% CI: 4.2-44.2, P= .004), and previous exposure to third-generation cephalosporins (95% CI: 2.2-16.4, P= .001) and fluoroquinolones (95% CI: 1.4-18.3; P= .003) were associated risks among CG I. Diabetes (95% CI: 1.6-15.4, P= .005), stroke (95% CI: 1.5-17.1, P= .001), and diarrhea (95% CI: 3.8-65.8, P= .001) were risks among CG II.
|
17980240 |
2007 |
|
Diabetes Mellitus
|
0.010 |
Biomarker
|
group |
BEFREE |
By multivariate analysis, diabetes (95% confidence interval [CI]: 1.9-13.2, P< .001), prior ESBL E coli colonization (<90 days) (95% CI: 1.2-67.8, P< .001), recent receipt of antibiotics (<90 days) (95% CI: 4.2-44.2, P= .004), and previous exposure to third-generation cephalosporins (95% CI: 2.2-16.4, P= .001) and fluoroquinolones (95% CI: 1.4-18.3; P= .003) were associated risks among CG I. Diabetes (95% CI: 1.6-15.4, P= .005), stroke (95% CI: 1.5-17.1, P= .001), and diarrhea (95% CI: 3.8-65.8, P= .001) were risks among CG II.
|
17980240 |
2007 |
|
Diarrhea
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
By multivariate analysis, diabetes (95% confidence interval [CI]: 1.9-13.2, P< .001), prior ESBL E coli colonization (<90 days) (95% CI: 1.2-67.8, P< .001), recent receipt of antibiotics (<90 days) (95% CI: 4.2-44.2, P= .004), and previous exposure to third-generation cephalosporins (95% CI: 2.2-16.4, P= .001) and fluoroquinolones (95% CI: 1.4-18.3; P= .003) were associated risks among CG I. Diabetes (95% CI: 1.6-15.4, P= .005), stroke (95% CI: 1.5-17.1, P= .001), and diarrhea (95% CI: 3.8-65.8, P= .001) were risks among CG II.
|
17980240 |
2007 |
|
Cerebrovascular accident
|
0.010 |
Biomarker
|
group |
BEFREE |
By multivariate analysis, diabetes (95% confidence interval [CI]: 1.9-13.2, P< .001), prior ESBL E coli colonization (<90 days) (95% CI: 1.2-67.8, P< .001), recent receipt of antibiotics (<90 days) (95% CI: 4.2-44.2, P= .004), and previous exposure to third-generation cephalosporins (95% CI: 2.2-16.4, P= .001) and fluoroquinolones (95% CI: 1.4-18.3; P= .003) were associated risks among CG I. Diabetes (95% CI: 1.6-15.4, P= .005), stroke (95% CI: 1.5-17.1, P= .001), and diarrhea (95% CI: 3.8-65.8, P= .001) were risks among CG II.
|
17980240 |
2007 |
|
Liver carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The four splicing sites, the variants generated by alternative splicing, and the humoral immune response in HCC patients, may help to analyze the role of kinectin in human HCC cell biology.
|
15060627 |
2004 |
|
Aplastic Anemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results suggest that kinectin may be a candidate autoantigen that is involved in the pathophysiology of AA.
|
12947009 |
2003 |
|
Autoimmune Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
No response to kinectin was detected in healthy volunteers, multiply transfused non-AA patients, or patients with other autoimmune diseases.
|
12947009 |
2003 |
|
Peroxisome biogenesis disorders
|
0.010 |
GeneticVariation
|
group |
BEFREE |
PEX1 mutation was delineated to be the genetic cause of PBD in the most highest incidence group, CG-E (the same as CG-I).
|
11330042 |
2000 |
|
DEAFNESS, AUTOSOMAL DOMINANT 5 (disorder)
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Mutation analysis of the CG1 gene in DFNA5 patients, however, could not reveal a disease-causing mutation.
|
9450185 |
1998 |